IDEAYA Biosciences Announces Successful US FDA Type C Meeting on Phase 2/3 Registrational Trial Designs to Support Potential Accelerated and Full Approval for IDE849, a Potential Best-in-Class DLL3 TOP1 ADC, in Neuroendocrine Carcinomas
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
IDEAYA Biosciences (Nasdaq: IDYA) outlined IDE849 registration plans for previously treated neuroendocrine carcinomas following a Type C FDA meeting.
The company plans an approximately 90-patient gastroenteropancreatic neuroendocrine carcinoma cohort targeting potential accelerated approval, using confirmed response rate assessed by blinded independent review. A planned randomized Phase 3 trial across multiple neuroendocrine carcinoma subtypes would assess progression-free survival for accelerated approval and overall survival for full approval. IDEAYA targets starting both studies and a Phase 3 trial after Imdelltra in extensive-stage small cell lung cancer by year-end 2026.
Partner Phase 1 data showed a 52.6% response rate among 19 patients, with 36.8% confirmed responses. In the separate global Phase 1/2 trial, severe treatment-related adverse event rates were 5% and 22.2% at the respective expansion doses.
How this balance works
Rhea-AI gives every point it takes from this document a weight. Minor counts 1, Moderate 3 and Major 9, so one Major point outweighs several Minor ones. The bar adds up the weights on each side, and when neither side holds more than 65% of the total the balance reads Mixed.
It reads the document as published, with the same rules for every company, and it does not look at what the market expected or at how the stock traded, so a point can be objectively good on a day the stock falls.
Rhea-AI Sentiment measures something else, the tone of the wording.
Hollow bars mark forward-looking points. How the balance works
Positive
- Moderate point. Forward-looking: it has not happened yet and may not happen.Approximately 90-patient cohort planned in previously treated gastroenteropancreatic neuroendocrine carcinoma to support potential accelerated approval.
- Moderate point. Forward-looking: it has not happened yet and may not happen.Randomized Phase 3 trial planned across neuroendocrine carcinoma subtypes, targeting full approval and additional subtype approvals.
- Minor point. Forward-looking: it has not happened yet and may not happen.Post-Imdelltra Phase 3 trial in extensive-stage small cell lung cancer targeted to start by year-end 2026.
- Minor pointFirst-line combination study designs remain under evaluation for extensive-stage small cell lung cancer.
- Minor pointPhase 1 response rate was 52.6% (10/19); confirmed response rate was 36.8% (7/19) in neuroendocrine carcinomas.
3 minor points
- Minor pointDisease control rate was 84.2% (16/19) among Phase 1 patients with neuroendocrine carcinomas.
- Minor pointMedian progression-free survival was 7.0 months in Phase 1 neuroendocrine carcinoma patients.
- Minor pointEstimated nine-month overall survival was 82.4% in Phase 1 neuroendocrine carcinoma patients.
Negative
- Minor pointGrade ≥3 treatment-related adverse events occurred in 5% (1/20) at 2.4 mg/kg and 22.2% (4/18) at 3.5 mg/kg.
- Minor pointInterstitial lung disease occurred at Grade 1–2 in 6.6% (8/122) and Grade ≥3 in 0.8% (1/122) in Phase 1.
News Explained
The company reports that the FDA Type C meeting on IDE849 registrational designs was successful and completed; the cohort and trials are still planned, not initiated, so this updates design alignment rather than trial initiation or approval.
Key Figures
- Extension cohort
- Approximately 90 patients
- Planned refractory GEP-NEC cohort
- Registrational trial initiation
- By the end of 2026
- Planned NEC trials and potential single-arm extension cohort
- ORR
- 52.6% (10/19)
- IDE849 Phase 1/2 data in NEC
- Confirmed ORR
- 36.8% (7/19)
- IDE849 Phase 1/2 data in NEC
- Median PFS
- 7.0 months
- IDE849 Phase 1/2 data in NEC
- Nine-month OS rate
- Estimated 82.4%
- IDE849 Phase 1/2 data in 2L+ NEC
- Grade ≥3 TRAE rate
- 5% (1/20)
- 2.4 mg/kg expansion dose
- Grade ≥3 TRAE rate
- 22.2% (4/18)
- 3.5 mg/kg expansion dose
Previous Clinical trial Reports
-
Updated IDE849 Phase 1 data included 36.8% confirmed response among 19 neuroendocrine carcinoma patients.
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
Key Terms
antibody drug conjugate medical
blinded independent central review medical
overall response rate medical
progression free survival medical
overall survival medical
interstitial lung disease medical
AI-generated analysis. How Rhea-AI works. Not financial advice.
- Single-arm extension cohort of approximately 90 refractory GEP-NEC patients to support potential accelerated approval, with ORR by BICR as the primary endpoint
- Randomized Phase 3 trial in multiple refractory NEC subtypes, including GEP-NEC and LC-NEC, is planned to support full approval, with OS as the primary endpoint
- IDE849 has demonstrated a
52.6% ORR (10/19), median PFS of 7.0 months, and an estimated 9-month OS rate of82.4% in 2L+ NEC - Global Phase 1/2 trial of IDE849 has shown a Grade ≥3 TRAE rate of
5% (1/20) and22.2% (4/18) at the 2.4 mg/kg and 3.5 mg/kg expansion doses, respectively - IDEAYA is targeting to initiate two randomized Phase 3 registrational trials in the refractory NEC and post-Imdelltra ES-SCLC settings, and a potential registration-enabling single-arm extension cohort in refractory GEP-NEC, by the end of 2026
"NEC is an aggressive disease with limited treatment options after first-line platinum-based chemotherapy. Our recent IDE849 data presented at ESMO in refractory NEC provides strong support for the clinical benefit that a DLL3-targeted ADC may offer for patients with this devastating disease," said Yujiro S. Hata, President and Chief Executive Officer of IDEAYA Biosciences. "In light of the fast-evolving landscape of DLL3-targeting agents we have completed two Type C meetings with the
Registrational Strategy for IDE849 in NEC
Following a successful Type C meeting with the
IDEAYA also plans to submit a protocol for a randomized, confirmatory Phase 3 trial of IDE849 in multiple NEC subtypes, including GEP-NEC and large cell NEC (LC-NEC), to support trial initiation by the end of the year. The randomized Phase 3 trial is intended to verify clinical benefit and support conversion of the potential accelerated approval to full approval in GEP-NEC and to expand approval in additional NEC subtypes, including LC-NEC, with the primary endpoints of progression free survival (PFS) for accelerated approval and overall survival (OS) for full approval. IDEAYA expects this trial to be well underway to fully enrolled at the time of the anticipated topline results from the single-arm trial.
In ES-SCLC, IDEAYA is on track to initiate a randomized Phase 3 registrational trial of IDE849 monotherapy in the post-Imdelltra setting by the end of the year, while continuing to evaluate several potential first-line study designs based on rational combinations that could offer differentiated safety and efficacy compared to current treatment standards.
Clinical Data Supporting the NEC Registrational Strategy
In October 2026, IDEAYA's partner Hengrui presented updated Phase 1 results for IDE849 at doses ≥1.8 mg/kg IV Q3W at the European Society for Medical Oncology (ESMO) Congress. Among 19 patients with NECs, ORR was
About IDE849
IDE849 (SHR-4849) is an investigational ADC that combines a humanized anti-DLL3 IgG1 antibody with a TOP1 inhibitor payload through a cleavable linker. The program is designed to target DLL3-expressing cancers, including ES-SCLC and other NECs. In December 2024, IDEAYA licensed the global development and commercialization rights to IDE849 outside of
About NECs
High DLL3 expression has been reported across multiple solid tumor subtypes of NECs that remain areas of high unmet medical need with few treatment options, including GEP-NEC and large cell neuroendocrine carcinoma (LC-NEC). The projected annual incidence of GEP-NEC and LC-NEC globally (excluding
About IDEAYA Biosciences
IDEAYA is a precision medicine oncology company committed to the discovery, development, and commercialization of transformative therapies to address unmet medical needs in cancer. The company integrates small-molecule drug discovery, structural biology and bioinformatics with extensive capabilities in identifying and validating translational biomarkers to develop potentially first-in-class targeted therapies for selected patient populations. IDEAYA has built a robust pipeline of targeted therapies focused on synthetic lethality and antibody-drug conjugates, or ADCs, including bispecifics, with the goal of improving clinical outcomes for patients with cancer.
Forward-Looking Statements
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, including statements regarding IDEAYA's registrational strategy for IDE849 in NEC and ES-SCLC, including the planned expansion of Arm 5 of the Phase 1 study, the planned randomized confirmatory Phase 3 trial, and trial design, endpoints, patient population, enrollment, comparator, timing and dose selection; the potential for accelerated and full approval; and the potential clinical profile of IDE849. Such statements are subject to risks and uncertainties, including that the FDA's feedback from regulatory meetings is preliminary and nonbinding, and the FDA may subsequently require modifications to the proposed trial designs, endpoints, patient population, statistical analysis plan or regulatory strategy, or require additional data or trials; the FDA may determine that a single-arm study or overall response rate does not support accelerated approval, may require that a confirmatory trial be underway prior to approval, or that the trial results do not verify clinical benefit or support full approval; IDEAYA may experience delays in selecting a recommended Phase 3 dose or in initiating, enrolling, conducting or completing clinical trials; early clinical results, including those from a Phase 1 trial conducted by Hengrui in China, may not be reproduced in later trials; and other risks described in IDEAYA's filings with the Securities and Exchange Commission. IDEAYA undertakes no obligation to update forward-looking statements except as required by law.
Investor and Media Contact
IDEAYA Biosciences
Joshua Bleharski, Ph.D.
Chief Financial Officer
investor@ideayabio.com
View original content to download multimedia:https://www.prnewswire.com/news-releases/ideaya-biosciences-announces-successful-us-fda-type-c-meeting-on-phase-23-registrational-trial-designs-to-support-potential-accelerated-and-full-approval-for-ide849-a-potential-best-in-class-dll3-top1-adc-in-neuroendocrine-carc-302939594.html
SOURCE IDEAYA Biosciences, Inc.
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.